Home/Pipeline/Long-acting Leronlimab

Long-acting Leronlimab

Not Specified

PreclinicalPhase in progress

Key Facts

Indication

Not Specified

Phase

Preclinical

Status

Phase in progress

Company

CytoDyn

About CytoDyn

CytoDyn is a clinical-stage biotech focused on developing its sole asset, the CCR5-targeting monoclonal antibody leronlimab, primarily for solid-tumor oncology. The company has pivoted from earlier efforts in HIV and COVID-19 to concentrate on oncology, citing promising long-term survival data in metastatic breast cancer. Its strategy hinges on positioning leronlimab as a 'prime-and-pair' agent to sensitize 'cold' tumors to immune checkpoint inhibitors, while concurrently advancing a broad preclinical pipeline across multiple cancer types and inflammatory diseases.

View full company profile

Therapeutic Areas

Oncology Inflammation Infectious Disease

Other Not Specified Drugs

Drug	Company	Phase	Status
New TCM Formulations	China SXT Pharmaceuticals	Research / Pre-clinical	Development
Collaborative Program with Ferring	PharmaBiome	Research	Active
Lighthouse Pilot Product	Cipherome	Pilot	Launched 2020
Nitric Oxide + Collagen Delivery	Jellagen	Research	Active
Undisclosed	Authera	Pre-clinical	Active
mRNA Therapeutics Platform Application	Lupagen	Research	Active
PHYRAGO	Handa Pharmaceuticals	Approved	Active
TASCENSO ODT	Handa Pharmaceuticals	Approved	Active
Axulin	Housey Pharmaceutical Research Laboratories	Commercial	Active
PBI-04711	Phoenix Biotechnology	Pre-clinical	Active
Immunology Program	Ignite Biomedical	Discovery	Active
Sunobinop	Imbrium Therapeutics	Not specified	Active